1. Bajorek BV, Ogle SJ, Duguid MJ, Shenfield GM, Krass I, Bajorek BV, et al. Management of warfarin in atrial fibrillation: views of health professionals, older patients and their carers. Med J Aust. 2007;186:175–80.
2. Bristol-Myers Squibb Company. Coumadin (warfarin sodium) highlights of prescribing information. 2011. http://packageinsertsbmscom/pi/pi_coumadinpdf. Accessed 11 April 2013.
3. Australian government Department of Health and Ageing. Review of anticoagulation therapies in atrial fibrillation. 2012. http://wwwpbsgovau/reviews/atrial-fibrillation-files/issues-and-options-paperpdf. Accessed 29 April 2013.
4. Shah SV, Gage BF. Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation clinical perspective. Circulation. 2011;123:2562–70.
5. Aspen Pharma. Coumadin (warfarin sodium) product information. 2010. http://wwwaspenpharmacomau/product_info/pi/PI_Coumadinpdf. Accessed 11 April 2013.